Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
Australia's TGA approved REDEMPLO (plozasiran) as the first and only treatment for Familial Chylomicronemia Syndrome (FCS) in the country. The approval expands global access to the siRNA therapy, which is already approved in the US, Canada, and China, and has a positive opinion from the EMA.
Key figures
- Drug Name
- REDEMPLO (plozasiran)
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.